^
Association details:
| Biomarker: | ER mutation |
|---|---|
| Cancer: | Hormone Receptor Positive Breast Cancer |
| Drug: | Piqray (alpelisib) (PIK3CA inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors
Published date:
03/23/2020
Excerpt:
Correlating genetic alterations with outcome, we identified loss-of-function PTEN mutations in 25% of patients with resistance. ESR1 activating mutations also expanded in number and allele fraction during treatment and were associated with resistance.
Secondary therapy:
letrozole; exemestane
DOI:
10.1038/s43018-020-0047-1
Trial ID:
